핵의학

본문글자크기
  • [Nucl Med Commun .] Comparison of empagliflozin and sitagliptin therapy on myocardial perfusion reserve in diabetic patients with coronary artery disease

    울산의대 / 오민영, 최준호, 문대혁, 이철환*

  • 출처
    Nucl Med Commun .
  • 등재일
    2021 Sep 1
  • 저널이슈번호
    42(9):972-978. doi: 10.1097/MNM.0000000000001429.
  • 내용

    바로가기  >

    Abstract
    Background: Sodium-glucose co-transporter 2 inhibitors reduce the risk of cardiovascular events in type 2 diabetic patients with coronary artery disease (CAD); however, the underlying mechanisms remain unclear.

    Objectives: We compared the effects of empagliflozin vs. sitagliptin therapy on myocardial perfusion reserve (MPR) using dynamic single-photon emission computed tomography (SPECT) imaging.

    Methods: In total, 100 patients with type 2 diabetes, CAD and an MPR <2.5 were randomized to receive either empagliflozin (10 mg once daily) or sitagliptin (100 mg once daily). Dynamic SPECT examinations were performed at baseline and at 6 months. The primary endpoint was the percent change of global MPR. Evaluable SPECT data were available for 98 patients.

    Results: Baseline clinical characteristics and SPECT data were well balanced between the two groups. At a 6-month follow-up, the fasting glucose and glycated hemoglobin levels significantly decreased in both groups. Hematocrit and hemoglobin levels significantly increased in the empagliflozin group but not in the sitagliptin group. The global MPR significantly improved after treatment in both groups (34.5 ± 70.6%; P = 0.005 for empagliflozin vs. 22.4 ± 45.7%; P = 0.024 for sitagliptin). However, there was no significant difference in the global MPR between the two groups (P = 0.934). Similar findings were detected with regard to the regional MPR.

    Conclusion: Among patients with type 2 diabetes and CAD, both empagliflozin and sitagliptin significantly improved the global MPR with no significant difference between the groups.

     

     

    Affiliations

    Minyoung Oh 1, Joon Ho Choi 1, Seon-Ok Kim 2, Pil Hyung Lee 3, Jung-Min Ahn 3, Seung-Whan Lee 3, Dae Hyuk Moon 1, Cheol Whan Lee 3
    1Department of Nuclear Medicine.
    2Department of Clinical Epidemiology and Biostatistics.
    3Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

  • 편집위원

    myocardial SPECT가 당뇨화자에서의 CAD risk 예측이나 치료평가에 도움이 된다는 연구내용이 개인적으로도 관심이 있었고 실제 임상에 바로 적용가능하며 검사의 활성화 및 신뢰도 향상에도 도움이 되리라 생각됨.

    2021-10-19 14:49:58

  • 덧글달기
    덧글달기
       IP : 3.91.203.238

    등록